GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.
Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track
by Zacks Equity Research
Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.
Glaxo (GSK) Miss Earnings Estimates in Q4, Revenues Beat
by Indrajit Bandyopadhyay
Glaxo miss earnings estimates in the fourth quarter of 2020 but beats the same for revenues. Stock down.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.
Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.
Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen
by Zacks Equity Research
Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.
Regeneron (REGN) COVID-19 Cocktail Effective Against New Variants
by Zacks Equity Research
Regeneron (REGN) reports research data confirming that antibody REGEN-COV is effective against the SARS-CoV-2 variants.
Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.
Top Research Reports for Facebook, Novo Nordisk & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Novo Nordisk (NVO), and SAP SE (SAP).
Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer
by Zacks Equity Research
The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.
J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.
Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal
by Kinjel Shah
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
by Kinjel Shah
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
by Zacks Equity Research
Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline
Top Stock Reports for UnitedHealth, Netflix & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Netflix (NFLX), and Caterpillar (CAT).
5 Big ETF Stories of 2020 Worth Watching in 2021
by Sweta Killa
We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
by Zacks Equity Research
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
U.S. Dollar to Remain Weak in 2021? ETFs to Gain
by Sanghamitra Saha
U.S. dollar is expected to remain weak in 2021, after being beaten down this year.
The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK